• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

    9.000 -0.050 (-0.55%)
    Streaming Delayed Price Updated: 9:30 AM EDT, May 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 788
    Open 9.000
    Bid (Size) 8.870 (1)
    Ask (Size) 9.000 (5)
    Prev. Close 9.050
    Today's Range 9.000 - 9.000
    52wk Range 3.210 - 10.69
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
    From Coya Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +29.31%
    +29.31%
    1 Month
    -8.16%
    -8.16%
    3 Month
    +50.00%
    +50.00%
    6 Month
    +90.68%
    +90.68%
    1 Year
    +92.31%
    +92.31%

    More News

    Read More
    Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
    From Coya Therapeutics, Inc.
    Via Business Wire
    COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
    Via InvestorPlace
    Coya Therapeutics
    Via Talk Markets
    Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in BTIG Fireside Discussion
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
    Via Benzinga
    Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
    From Coya Therapeutics, Inc.
    Via Business Wire
    Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Closing of $26.5 Million Private Placement
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces $26.5 Million Private Placement
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
    From Coya Therapeutics, Inc.
    Via Business Wire
    Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
    Via MarketBeat
    Topics Bonds
    Exposures Debt Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.